A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris.
A double-blind placebo controlled study of angina pectoris with penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000627:therapeutic use; D003864:Depression, Chemical; D004311:Double-Blind Method; D006334:Heart Function Tests; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D005082:Physical Exertion; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D003517:Cyclopentanes; D011412:Propanolamines